Treatment of pediatric epilepsy in Poland

Dorota Dunin-Wąsowicz, Maria Mazurkiewicz-Bełdzińska, Barbara Steinborn, James Wheless, Sergiusz Jóźwiak

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background The many types of childhood epilepsies make the diagnosis and treatment difficult and the outcomes frequently poor. Furthermore, there are few clinical trials in pediatric epilepsy that provide useful results to guide daily practice. Therefore for pediatric neurologists expert opinion may be useful. Aims To provide an overview of current practice in Poland and compare results with European and US clinical guidelines. Methods Polish specialists in pediatric neurology were asked to participate in a survey about pediatric epilepsy. The focus of the questions was on the overall strategy and treatment options for different syndromic diagnoses. The survey was developed and performed according to a previous European survey (Wheless et al., 2007). Results Fifty-one Polish specialists, working in academic or clinical settings, completed the questionnaire. They limited combination therapy to two or three antiepileptic drugs. Valproate was the treatment of choice for myoclonic, generalized tonic-clonic seizures and Lennox-Gastaut syndrome. For infantile spasms caused by tuberous sclerosis and of symptomatic etiology, vigabatrin was treatment of choice; valproate and ACTH were other first line options. Valproate and ethosuximide were chosen for childhood absence epilepsy and valproate for juvenile absence epilepsy. Carbamazepine was the first-line treatment option for benign partial epilepsy of childhood with centrotemporal spikes and complex partial seizures. In the treatment of juvenile myoclonic epilepsy for males valproate, for females lamotrigine were chosen. Conclusion Polish pediatric neurologists agreed on the majority of questions. Their views reflect the clinical utility and availability of treatment options in Poland. Results may provide direction for clinicians.

Original languageEnglish (US)
Pages (from-to)320-326
Number of pages7
JournalEuropean Journal of Paediatric Neurology
Volume19
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Poland
Epilepsy
Valproic Acid
Pediatrics
Absence Epilepsy
Therapeutics
Seizures
Rolandic Epilepsy
Juvenile Myoclonic Epilepsy
Ethosuximide
Vigabatrin
Infantile Spasms
Tuberous Sclerosis
Partial Epilepsy
Carbamazepine
Expert Testimony
Neurology
Anticonvulsants
Adrenocorticotropic Hormone
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Dunin-Wąsowicz, D., Mazurkiewicz-Bełdzińska, M., Steinborn, B., Wheless, J., & Jóźwiak, S. (2015). Treatment of pediatric epilepsy in Poland. European Journal of Paediatric Neurology, 19(3), 320-326. https://doi.org/10.1016/j.ejpn.2014.12.023

Treatment of pediatric epilepsy in Poland. / Dunin-Wąsowicz, Dorota; Mazurkiewicz-Bełdzińska, Maria; Steinborn, Barbara; Wheless, James; Jóźwiak, Sergiusz.

In: European Journal of Paediatric Neurology, Vol. 19, No. 3, 01.05.2015, p. 320-326.

Research output: Contribution to journalArticle

Dunin-Wąsowicz, D, Mazurkiewicz-Bełdzińska, M, Steinborn, B, Wheless, J & Jóźwiak, S 2015, 'Treatment of pediatric epilepsy in Poland', European Journal of Paediatric Neurology, vol. 19, no. 3, pp. 320-326. https://doi.org/10.1016/j.ejpn.2014.12.023
Dunin-Wąsowicz D, Mazurkiewicz-Bełdzińska M, Steinborn B, Wheless J, Jóźwiak S. Treatment of pediatric epilepsy in Poland. European Journal of Paediatric Neurology. 2015 May 1;19(3):320-326. https://doi.org/10.1016/j.ejpn.2014.12.023
Dunin-Wąsowicz, Dorota ; Mazurkiewicz-Bełdzińska, Maria ; Steinborn, Barbara ; Wheless, James ; Jóźwiak, Sergiusz. / Treatment of pediatric epilepsy in Poland. In: European Journal of Paediatric Neurology. 2015 ; Vol. 19, No. 3. pp. 320-326.
@article{91b85c4e5c5942c18a997d4ca50090e6,
title = "Treatment of pediatric epilepsy in Poland",
abstract = "Background The many types of childhood epilepsies make the diagnosis and treatment difficult and the outcomes frequently poor. Furthermore, there are few clinical trials in pediatric epilepsy that provide useful results to guide daily practice. Therefore for pediatric neurologists expert opinion may be useful. Aims To provide an overview of current practice in Poland and compare results with European and US clinical guidelines. Methods Polish specialists in pediatric neurology were asked to participate in a survey about pediatric epilepsy. The focus of the questions was on the overall strategy and treatment options for different syndromic diagnoses. The survey was developed and performed according to a previous European survey (Wheless et al., 2007). Results Fifty-one Polish specialists, working in academic or clinical settings, completed the questionnaire. They limited combination therapy to two or three antiepileptic drugs. Valproate was the treatment of choice for myoclonic, generalized tonic-clonic seizures and Lennox-Gastaut syndrome. For infantile spasms caused by tuberous sclerosis and of symptomatic etiology, vigabatrin was treatment of choice; valproate and ACTH were other first line options. Valproate and ethosuximide were chosen for childhood absence epilepsy and valproate for juvenile absence epilepsy. Carbamazepine was the first-line treatment option for benign partial epilepsy of childhood with centrotemporal spikes and complex partial seizures. In the treatment of juvenile myoclonic epilepsy for males valproate, for females lamotrigine were chosen. Conclusion Polish pediatric neurologists agreed on the majority of questions. Their views reflect the clinical utility and availability of treatment options in Poland. Results may provide direction for clinicians.",
author = "Dorota Dunin-Wąsowicz and Maria Mazurkiewicz-Bełdzińska and Barbara Steinborn and James Wheless and Sergiusz J{\'o}źwiak",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.ejpn.2014.12.023",
language = "English (US)",
volume = "19",
pages = "320--326",
journal = "European Journal of Paediatric Neurology",
issn = "1090-3798",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Treatment of pediatric epilepsy in Poland

AU - Dunin-Wąsowicz, Dorota

AU - Mazurkiewicz-Bełdzińska, Maria

AU - Steinborn, Barbara

AU - Wheless, James

AU - Jóźwiak, Sergiusz

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background The many types of childhood epilepsies make the diagnosis and treatment difficult and the outcomes frequently poor. Furthermore, there are few clinical trials in pediatric epilepsy that provide useful results to guide daily practice. Therefore for pediatric neurologists expert opinion may be useful. Aims To provide an overview of current practice in Poland and compare results with European and US clinical guidelines. Methods Polish specialists in pediatric neurology were asked to participate in a survey about pediatric epilepsy. The focus of the questions was on the overall strategy and treatment options for different syndromic diagnoses. The survey was developed and performed according to a previous European survey (Wheless et al., 2007). Results Fifty-one Polish specialists, working in academic or clinical settings, completed the questionnaire. They limited combination therapy to two or three antiepileptic drugs. Valproate was the treatment of choice for myoclonic, generalized tonic-clonic seizures and Lennox-Gastaut syndrome. For infantile spasms caused by tuberous sclerosis and of symptomatic etiology, vigabatrin was treatment of choice; valproate and ACTH were other first line options. Valproate and ethosuximide were chosen for childhood absence epilepsy and valproate for juvenile absence epilepsy. Carbamazepine was the first-line treatment option for benign partial epilepsy of childhood with centrotemporal spikes and complex partial seizures. In the treatment of juvenile myoclonic epilepsy for males valproate, for females lamotrigine were chosen. Conclusion Polish pediatric neurologists agreed on the majority of questions. Their views reflect the clinical utility and availability of treatment options in Poland. Results may provide direction for clinicians.

AB - Background The many types of childhood epilepsies make the diagnosis and treatment difficult and the outcomes frequently poor. Furthermore, there are few clinical trials in pediatric epilepsy that provide useful results to guide daily practice. Therefore for pediatric neurologists expert opinion may be useful. Aims To provide an overview of current practice in Poland and compare results with European and US clinical guidelines. Methods Polish specialists in pediatric neurology were asked to participate in a survey about pediatric epilepsy. The focus of the questions was on the overall strategy and treatment options for different syndromic diagnoses. The survey was developed and performed according to a previous European survey (Wheless et al., 2007). Results Fifty-one Polish specialists, working in academic or clinical settings, completed the questionnaire. They limited combination therapy to two or three antiepileptic drugs. Valproate was the treatment of choice for myoclonic, generalized tonic-clonic seizures and Lennox-Gastaut syndrome. For infantile spasms caused by tuberous sclerosis and of symptomatic etiology, vigabatrin was treatment of choice; valproate and ACTH were other first line options. Valproate and ethosuximide were chosen for childhood absence epilepsy and valproate for juvenile absence epilepsy. Carbamazepine was the first-line treatment option for benign partial epilepsy of childhood with centrotemporal spikes and complex partial seizures. In the treatment of juvenile myoclonic epilepsy for males valproate, for females lamotrigine were chosen. Conclusion Polish pediatric neurologists agreed on the majority of questions. Their views reflect the clinical utility and availability of treatment options in Poland. Results may provide direction for clinicians.

UR - http://www.scopus.com/inward/record.url?scp=84926250253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926250253&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2014.12.023

DO - 10.1016/j.ejpn.2014.12.023

M3 - Article

VL - 19

SP - 320

EP - 326

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 3

ER -